# A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

> **NCT04238819** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 47 (actual)

## Conditions studied

- Relapsed Solid Tumor
- Refractory Solid Tumor

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide
- **DRUG:** Dinutuximab
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT04238819
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-09
- **Primary completion:** 2024-03-15
- **Final completion:** 2025-08-19
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238819, "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04238819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*